Vertex Pharmaceuticals IncorporatedVRTX

Vertex Pharmaceuticals focuses on discovering and marketing innovative treatments, primarily for cystic fibrosis (CF). Its portfolio includes KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI, and TRIKAFTA, which target specific CFTR gene mutations. Beyond CF, the pipeline includes VX-880 for Type 1 Diabetes, VX-548 for pain, and CTX001 for sickle cell disease and beta-thalassemia. Vertex distributes globally through specialty networks and maintains strategic R&D collaborations with partners like CRISPR Therapeutics and Moderna.